Dermatological Drugs Global Market Report 2025

The dermatological drugs market size has grown strongly in recent years. It will grow from $20.06 billion in 2024 to $22.04 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth during the historic period was driven by the rising prevalence of skin disorders, advancements in drug formulation and delivery, increasing awareness of skincare and aesthetics, the expansion of the aging population, and the growing demand for over-the-counter dermatological products.

The dermatological drugs market size is expected to see strong growth in the next few years. It will grow to $31.75 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. The projected growth in the forecast period can be attributed to advancements in biologics and targeted therapies, the increasing adoption of teledermatology and digital health, a rising prevalence of lifestyle-related skin conditions, growing demand for personalized and regenerative medicine, and expanding research in microbiome-based dermatological treatments. Key trends expected in this period include nanotechnology-based drug delivery, AI-driven dermatological diagnostics, microbiome-targeted therapies, 3D bioprinting for skin regeneration, gene editing, and RNA-based treatments.

The increasing demand for cosmetic dermatology procedures is expected to drive the expansion of the dermatological drugs market. Cosmetic dermatology is a specialized field that enhances a person's appearance through various non-surgical treatments and procedures. This growing demand is fueled by heightened consumer awareness of aesthetic treatments, advancements in skincare technology, and a preference for non-invasive procedures to improve appearance and counteract aging. The rising popularity of cosmetic dermatology treatments, such as anti-aging and skin rejuvenation procedures, is leading to the development of advanced dermatological drugs that provide safe, effective, and minimally invasive solutions. For example, in January 2023, the International Society of Aesthetic Plastic Surgery reported that over 12.8 million surgical and 17.5 million non-surgical procedures were performed globally, reflecting a 19.3% increase from the previous period. Additionally, in 2022, plastic surgeons worldwide conducted more than 14.9 million surgical and 18.8 million non-surgical procedures, marking an 11.2% rise in total treatments. As a result, the growing number of cosmetic dermatology procedures is fueling the expansion of the dermatological drugs market.

Leading companies in the dermatological drugs market are focusing on developing biologic treatments to address chronic skin conditions such as psoriasis, atopic dermatitis, and hidradenitis suppurativa. Biologic therapies target specific immune pathways, offering more effective and long-lasting relief compared to traditional treatments. In September 2024, Eli Lilly and Company, a US-based pharmaceutical firm, received approval for Ebglyss (lebrikizumab), an interleukin-13 (IL-13) inhibitor designed to treat moderate-to-severe atopic dermatitis in patients aged 12 and older. This approval represents a significant advancement, providing a new biologic treatment option for individuals who have not achieved sufficient symptom control with topical therapies. Ebglyss aims to enhance patients' quality of life by reducing severe itching and skin inflammation associated with moderate-to-severe atopic dermatitis.

In September 2024, Organon, a US-based pharmaceutical company, acquired Dermavant Sciences Ltd. for $1.2 billion. This acquisition brings Dermavant's flagship product, VTAMA (tapinarof) cream, 1%, into Organon’s portfolio. VTAMA is a non-steroidal topical treatment approved by the US Food and Drug Administration (FDA) for mild, moderate, and severe plaque psoriasis in adults. Dermavant Sciences Ltd. is a US-based immunodermatology company specializing in the development and commercialization of innovative dermatological treatments.

Major players in the dermatological drugs market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, AstraZeneca plc, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Bausch Health Companies Inc., Organon International, Galderma, Incyte Corporation, Glenmark Pharmaceuticals Ltd., Mayne Pharma Group Limited, Dermavant Sciences Inc., Taro Pharmaceutical Industries Ltd., Biofrontera AG, Almirall SA, UCB SA, LEO Pharma A/S, and Dermira Inc.

North America was the largest region in the dermatological drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dermatological drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dermatological drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Dermatological drugs are medications formulated to treat conditions affecting the skin, hair, and nails by reducing inflammation, controlling infections, and managing symptoms such as itching and redness. These drugs are essential in dermatology, helping to address both common and severe skin disorders while enhancing patient comfort and quality of life.

The primary drug classes in dermatological treatments include corticosteroids, retinoids, antibiotics, antifungals, calcineurin inhibitors, and others. Corticosteroids are a class of steroid hormones that reduce inflammation and suppress immune system activity by mimicking cortisol, a natural hormone produced by the adrenal glands. These drugs can be administered through various routes, including topical, oral, and parenteral administration. They are used to treat multiple conditions such as acne, psoriasis, rosacea, alopecia, and more. Distribution channels include hospital pharmacies, retail pharmacies, and other outlets.

The dermatological drugs market research report is one of a series of new reports that provides dermatological drugs market statistics, including dermatological drugs industry global market size, regional shares, competitors with a dermatological drugs market share, detailed dermatological drugs market segments, market trends and opportunities, and any further data you may need to thrive in the dermatological drugs industry. This dermatological drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dermatological drugs market consists of sales of creams, ointments, gels, and lotions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.